Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy

Under standardized conditions (drug and light dose, timing), the result of the photodynamic therapy (PDT) of carcinomas of the esophagus with tetra(meta‐hydroxy‐phenyl)chlorin (mTHPC) shows large variations between patients.

[1]  M C Berenbaum,et al.  Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. , 1989, The Biochemical journal.

[2]  Daniel Braichotte,et al.  Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths , 1995, International journal of cancer.

[3]  H. Bergh,et al.  Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. , 1994, Cancer research.

[4]  U Althaus,et al.  Effect of drug‐light interval on photodynamic therapy with meta‐tetrahydroxyphenylchlorin in malignant mesothelioma , 1993, International journal of cancer.

[5]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[6]  M. C. Berenbaum,et al.  Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. , 1991, British journal of cancer.

[7]  J Moan,et al.  Evaluation of a new photosensitizer, meso‐tetra‐hydroxyphenyl‐chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizers , 1994, International journal of cancer.

[8]  G. Wagnières,et al.  Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi , 1995, Cancer.

[9]  S. Lam.  Photodynamic therapy of lung cancer. , 1993, Thorax.

[10]  M. Pantelides,et al.  THE UPTAKE OF PORPHYRIN AND ZINC‐METALLOPORPHYRIN BY THE PRIMATE PROSTATE , 1993, Photochemistry and photobiology.